MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
29.31
-1.04
-3.43%
After Hours: 29.00 -0.31 -1.06% 19:33 01/09 EST
OPEN
30.70
PREV CLOSE
30.35
HIGH
30.70
LOW
29.03
VOLUME
548.51K
TURNOVER
--
52 WEEK HIGH
30.70
52 WEEK LOW
6.42
MARKET CAP
1.56B
P/E (TTM)
-15.5937
1D
5D
1M
3M
1Y
5Y
1D
Tyra Biosciences (TYRA) Is Up 9.4% After New COO Hire And 52-Week High Has The Bull Case Changed?
Simply Wall St · 11h ago
TYRA BIOSCIENCES INC <TYRA.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $32 FROM $28
Reuters · 6d ago
Bank of America Securities Sticks to Its Buy Rating for Tyra Bioscience (TYRA)
TipRanks · 6d ago
Weekly Report: what happened at TYRA last week (1229-0102)?
Weekly Report · 6d ago
U.S. RESEARCH ROUNDUP-Adobe, Eli Lilly, First Citizens Bancshares
Reuters · 6d ago
Weekly Report: what happened at TYRA last week (1222-1226)?
Weekly Report · 12/29/2025 10:05
Tyra Biosciences (TYRA): Assessing Valuation After New Leadership Hires and Biotechnology Index Inclusion
Simply Wall St · 12/26/2025 01:21
Weekly Report: what happened at TYRA last week (1215-1219)?
Weekly Report · 12/22/2025 10:05
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.